Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because ...

Screening VHH pairs creates an unbiased pool of antibodies with broader functionality, and through selection of optimal linkers even low-affinity, single-epitope binders function synergistically ...

a trispecific antibody designed as a prophylaxis and therapeutic against SARS-CoV-2 infection. Using in-house phage libraries of naïve and synthetic humanized llama nanobodies (VHH), the Ab ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

About VINCOBODIES VINCOBODIES are an advancement in antibody engineering ... the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology.

Humanization of mouse monoclonal antibodies or alpaca nanobody by genetic engineering can increase their similarity to antibodies naturally produced in humans, greatly enhancing their in vivo ...

Schematic overview of different antibody formats. Conventional mAb, HcAb and its derivative (i.e., nanobody, also referred to as the variable domain of the heavy chain of a HcAb or VHH).

The presence of anti-drug-antibodies (ADA) has been the key determinant ... of ADAs against several experimental camelid VHH biologics (Nanobodies®). Hereafter, we refer to this assay as WESADA.

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on inflammation and immunology biological products and contract develo ...